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Background: Malaria transmission continues to occur in Haiti, with 25,423 confirmed cases of Plasmodium falciparum
and 161,236 suspected infections reported in 2012. At low prevalence levels, passive surveillance measures, which rely
primarily on reports from health systems, becomes less appropriate for capturing annual malaria incidence. To improve
understanding of malaria transmission in Haiti, participants from the Ouest and Sud-Est departments were screened
using a highly sensitive enzyme-linked immunosorbent assay (ELISA).
Methods: Between February and May 2013, samples were collected from four different sites including a rural
community, two schools, and a clinic located in the Ouest and Sud-Est departments of Haiti. A total of 815 serum
samples were screened for malaria antibodies using an indirect ELISA coated with vaccine candidates apical membrane
antigen (AMA-1) and merozoite surface protein-1 (MSP-119). The classification of previous exposure was established by
using a threshold value that fell three standard deviations above the mean absorbance for suspected seronegative
population members (OD of 0.32 and 0.26 for AMA-1 and MSP-1, respectively). The observed seroprevalence values
were used to fit a modified reverse catalytic model to yield estimates of seroconversion rates.
Results: Of the samples screened, 172 of 815 (21.1%) were AMA-1 positive, 179 of 759 (23.6%) were MSP-119 positive,
and 247 of 815 (30.3%) were positive for either AMA-1 or MSP-1; indicating rates of previous infections between 21.1%
and 30.3%. Not surprisingly, age was highly associated with the likelihood of previous infection (p-value <0.001). After
stratification by age, the estimated seroconversion rate indicated that the annual malaria transmission in the Ouest and
Sud-Est department is approximately 2.5% (95% CI SCR: 2.2%, 2.8%).
Conclusions: These findings suggest that despite the absence of sustained malaria control efforts in Haiti, transmission
has remained relatively low over multiple decades. Elimination in Haiti appears to be feasible; however, surveillance
must continue to be strengthened in order to respond to areas with high transmission and measure the impact of
future interventions.
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Over the past decade there has been a renewed interest
in eliminating malaria from the island of Hispaniola,
with a bi-national strategy recently adopted between the
Dominican Republic and Haiti to eliminate malaria by
2020 [1]. Recent reports of emerging chloroquine resist-
ance in Haiti [2], coupled with increased international
aid, present a time sensitive window in which malaria
control efforts should be scaled up, before treatment
strategies must switch to more expensive combination
therapies [3]. Furthermore, only one species of malaria
parasite is present in Haiti, Plasmodium falciparum, and
the principal mosquito responsible for malaria transmis-
sion, Anopheles albimanus, is primarily zoophilic mak-
ing it a poor vector of disease [1]. Finally there is little
chance of malaria being reintroduced into Haiti once it
has been successfully eliminated [4].
Although transmission continues to occur in Haiti, with
25,423 confirmed cases and 161,236 suspected infections
reported in 2012 [5], findings from a 2012 country wide
cross-sectional survey administered by Population Services
International suggest parasite prevalence rates to be <1%
[1]. However, focal transmission has been documented by
other studies, with parasite rates in the Artibonite Valley of
3.1% [6], and parasite rates ranging from 0-34% in the
Sud-Est Department [7], indicating persistent and hetero-
geneous malaria transmission.
As Haiti gears up for malaria elimination, obtaining
sensitive measurements of malaria transmission will be
crucial to monitoring the impact of control efforts adopted
to achieve this goal [8]. In low transmission settings, there
is a tendency to rely on passive malaria surveillance over
active surveillance due to budgetary constraints; however,
passive surveillance is not as sensitive at accurately captur-
ing malaria incidence, especially in areas with poor health
infrastructure like Haiti. To overcome this difficultly, sero-
logical markers of malaria have been used to determine
malaria exposure rates in low transmission settings, allow-
ing researchers to estimate seroconversion rates (SCR) by
modelling the age specific seroprevalence [9-15]. Recently,
a study by Arnold et al. examined cross-sectional and
longitudinal data from 1991-1998 using merozoite surface
protein-119 (MSP-1), and found the SCR to be roughly
2.3% in Leogane, which is located in the Ouest department
of Haiti [12]. Estimating malaria transmission by meas-
uring long-lasting antibody responses generated from
previous malaria infections also allows the investigation
of long-term trends without the estimated serocon-
version rates being skewed by seasonal transmission,
which is appropriate in this setting since the endemic-
epidemic state of malaria coincides closely with rainfall
patterns in Haiti [10,16].
The purpose of this study was to provide valuable in-
formation on current trends in malaria transmission inthe Ouest and Sud-Est departments of Haiti by analysing
data collected in 2013 with ELISA techniques employing
more than one P. falciparum specific antigen. This data
adds to the current body of literature on malaria in
Haiti, while providing policy-makers baseline informa-
tion on malaria transmission rates in these regions that
support the rationale for malaria elimination in Haiti.
Methods
Study location and enrollment
The samples analysed in this study were collected from
four sites located in the Ouest and Sud-Est department of
Haiti in the communes of Gressier and Jacmel, between
February and May 2013. A map of Haiti including the en-
rollment locations, study communes, and departments is
presented in Figure 1. Enrollment was based on conveni-
ence sampling from both clinical and non-clinical settings,
as part of a larger study on host protective genetic factors
[17]. Study sites included a rural community, two schools,
and a clinic located in the Ouest and Sud-Est departments
of Haiti, with participation open to all individuals attend-
ing each site. Healthy children were enrolled from the
Christianville School in Gressier and from the Hossana
Baptist School in Jacmel. Patients and healthy family
members attending Portail Leogane Clinic in Jacmel were
enrolled on a voluntary basis. Individuals from Chabin
were enrolled from community members seeking general
health services at a mobile clinic. Participants at each
location were given opportunities to ask the enrolling
physicians questions during information sessions prior to
consent. After obtaining consent from participants or their
guardian, local clinicians collected approximately 3 ml of
blood by venipuncture into serum separation tubes from
participants, which were centrifuged immediately at 6,000
RPM for two minutes after collection was complete. All
serum samples were stored at -80°C in the University of
Florida field laboratory in Gressier, until shipment to the
Emerging Pathogens Institute, in Gainesville, FL, for
analysis and storage. Serum samples were collected from a
total of 823 participants between the ages of two and 80.
Malaria infected participants (5/823), determined via rapid
diagnostic test (RDT) were excluded from analysis to
reduce the effect of positive individuals seeking treatment
for current infections. Participants missing age data (3/
823) were also excluded, resulting in a final sample size of
815 (483 females and 332 males). Of the 815 samples
analysed, all were screened for previous exposure using
the antigen AMA-1, but only 759/815 samples were
screened using the MSP-1, due to limited amounts of
serum from some participants.
Ethical approval
Ethical approval to conduct this research was obtained
from the Haitian-based Ethical Review Committee, the
Figure 1 Map of Haiti with the location of the study enrollment sites. The four study enrollment sites located inside the Ouest and Sud-Est
Departments of Haiti in the communes of Gressier and Jacmel. Participants were enrolled from Christianville School in Gressier and from Hosana
Baptist School and Portail Leogane Clinic, and the rural community of Chabin in Jacmel. Along with an inset of the entire country of Haiti, the
enrollment sites (red circles) appear relative to the study commune (yellow), the national capital (star) and national highway systems (pink lines).
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Office of Research Protections, United States Army
Medical Research and Materials Command.
ELISA protocol and procedures
Serum samples were screened for antibodies against AMA-
1 and MSP-119 using an indirect enzyme-linked immu-
nosorbent assay (ELISA). Serum samples of subjects were
diluted in 5% non-fat skim milk in phosphate buffered sa-
line (NFSM-PBS). ELISA plates were coated in duplicate
with the respective antigen diluted in 5% NFSM-PBS to a
final concentration of 1 ml/ml for AMA-1 and 0.5 ml/ml
for MSP-1, before overnight incubation at 4°C. The next
day, antigen was removed and plates were washed five
times with 0.05% tween-20 in PBS-K and then blocked for
one hour with 5% NFSM-PBS to reduce non-selective bind-
ing. Following additional wash, diluted serum samples as
well as positive and negative control sera were plated in du-
plicate and incubated for two hours at 4°C. Horseradish
peroxidase conjugated rabbit anti-human IgG secondary
antibody was diluted 1:1,000 in 5% NFSM-PBS and added
to the plate. After one hour, plates were washed seven times
and treated with 3,3’, 5,5’-tetramethylbenzidine (TMB) sub-
strate solution in the dark for 20 minutes to allow sufficient
colour development and stopped with 2 M sulfuric acid.Determination of seropositive and seronegative
population members
After measurement of the samples in duplicate, the aver-
age absorbance at 450 nm was used to determine the
thresholds for the classification of a sample as seropositive
or seronegative. Given the low incidence and relatively
large sample size for each antigen (n = 815 or 759), the
seronegative population responses for AMA-1 and MSP-1
should follow a normal distribution function with sample
mean μ^ and sample standard deviation σ^ . This behaviour
is presented in Figure 2, where the suspected seronega-
tive populations approximated normal distributions with
μ^ ¼ 0:191; 0:140 and σ^ ¼ 0:0427; 0:04 for AMA-1 and
MSP-1, respectively. Thresholds for positive AMA-1
and MSP-1 responses were classified by the addition of
three, four, and five sample standard deviations to the
sample mean, such that ≥ 99.7% of seronegative popula-
tion members would not be classified as seropositive.
The resulting thresholds using three, four, and five,
sample deviations for AMA-1 were 0.319, 0.362, 0.405
and 0.260, 0.30, 0.340 for MSP-1. Responses above three
standard deviations of the mean suspected average were
considered seropositive, given the minimal impact using
more conservative thresholds had on the estimated preva-
lence (see Discussion).
Figure 2 Distribution of ELISA responses in absorbance units (λ= 450 nm). The distribution of ELISA responses from the study participants in
absorbance units (at 450 nm) appear for AMA-1 and MSP-1 on the left and right panels of Figure 2, respectively. The upper panels show the histograms of
the suspected seronegative ELISA results overlaid with a normal distribution function. The sample mean (thick black line) and sample standard deviation of
these functions were used to determine minimum absorbance values (thresholds) for the classification of a sample as seropositive using the sample mean
for the suspected negative population members plus three to five sample standard deviations (gold, orange, and red dashed lines).
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The observed cross-sectional seroprevalence was used to
estimate the seroconversion rate using a method similar to
those previously described [11,18]. Briefly, an age specific
seroconversion model was fit to the prevalence of AMA-1,
MSP-1, and AMA-1 or MSP-1 seropositive population
members using all participants (aged 2 to 80) and separately
for participants less than 20 years of age to estimate the rate
of seroconversion (λ). Participants were separated into “age
classes” to depict aggregated seroprevalence, with wider age
ranges used in older groups, due to the lower number of
participants over the age of 20. Since the AMA-1 and
MSP-1 responses are long-lasting and the estimation of
reversion rates has been suggested to be unreliable with
cross-sectional data, a reversion rate (ρ) of zero was used
for the final analysis [13], however non zero reversion rates
were also explored. Without seroreversion, the probability
of infection (prevalence) at age x was modeled using the
equation P(x) = [1 ‐ exp(−λ * x)]. When seroreversion was
included in the model, the probability at age x was modeled
using the equation P(x) = λ/(λ + ρ) [1 ‐ exp(−(λ + ρ)x)]. The
functions were optimized (using R) to give estimated sero-
conversion/reversion rates λ^ and ρ^, as well as their standard
errors for the calculation of 95% confidence intervalsfor λ^ and ρ^ . Odds ratios for the probability of having a
previous exposure, as determined by a positive ELISA
response, were calculated using a simple logistic regres-
sion by age category.
Results
Estimation of seroprevalence using AMA-1 and MSP-1
Characteristics of the resulting study population can be
found in Table 1.
Using the average absorbance from each serum sample
and a threshold of three standard deviations from the
sample mean to indicate the presence of AMA-1 or
MSP-1 antibodies, 172 of 815 (21.1%) had the presence
of AMA-1 antibodies, 179 of 759 (23.6%) had the pres-
ence of MSP-1 antibodies, and 247 of 815 (30.3%) had
the presence of either AMA-1 or MSP-1 antibodies.
Using thresholds from three to five standard deviations
gave similar estimates of seroprevalence that ranged
from 16.3% to 21.1% for AMA-1, 17.4% to 23.6% for
MSP-1 and 24.0% to 30.3% for either AMA-1 or MSP-1.
The seroprevalence by age group (ranging from 2 to
80 years) is presented in Table 2 and Figure 3.
As expected, the prevalence of seropositive partici-
pants increases with participant age. The prevalence of
Table 1 Study population characteristics by site of enrollment
Demographic factors Participants given ELISA
Site of enrollment Size Age Gender AMA-1 MSP-1 Combined
(N) Years % Male No. tests No. tests No. tests
Christianville school 510 12.2 41.4 510 461 510
Hosana Baptist school 102 8.29 52 102 102 102
Portail Leogane clinic 72 28.9 29.2 72 72 72
Chabin community 131 29.8 35.9 131 124 131
Total 815 16.1 40.7 815 759 815
The total number of total samples, average age in years, percentage of male participants, and the number of participants who were screened using an ELISA with
AMA-1, MSP-1, or either AMA-1 or MSP-1 antigens are listed by study enrollment site.
von Fricken et al. Malaria Journal 2014, 13:361 Page 5 of 8
http://www.malariajournal.com/content/13/1/361previous infections determine by AMA-1 response was
not significantly different (p value > 0.05) between age
classes under 20 years of age. However compared to
participants younger than 20 years of age, the likelihood of
previous infection in those over 20 years of age was 6.0
times higher (95% CI OR 4.03, 8.99). For MSP-1 re-
sponses, differences in prevalence compared to the youn-
gest age class were significant (p value = 0.023) beginning
at the third age class (9 to 13 years of age), with those over
20 years of age having 3.7 times the likelihood of previous
infection (O.R. – 3.7; 95% CI = 2.48, 5.53). Of participants
who were tested with both AMA-1 and MSP-1 (n = 759),
104 were classified as seropositive using both antigens
(13.7%), 75 were MSP-1 positive and AMA-1 negative
(9.9%), 57 were AMA-1 positive and MSP-1 negative
(7.5%), and 523 were negative for both AMA-1 and MSP-
1 (68.9%). The distribution of positive ELISA responses
for AMA-1 or MSP-1 antigens appears graphically in
Figure 4, with regions I, II, III, and IV representing the
average absorbance value for the response to the AMA-1
and MSP-1 antigens for samples with AMA-1(+)/MSP-1
(+) results, AMA-1(-)/MSP-1 (+) results, AMA-1(+)/MSP-
1(-) results, and AMA-1 (-)/MSP-1(-) results, respectively.Table 2 Number and prevalence of seropositive participants b
Age class AMA-1
(years) n No. Pos. % Pos. n
2 to 5 61 4 6.6 61
6 to 9 190 26 13.7 189
9 to 13 216 33 15.3 193
14 to 17 154 25 16.2 129
18 to 20 63 16 25.4 60
21 to 29 40 14 35.0 40
30 to 49 50 26 52.0 48
over 50 41 28 68.3 39
Total 815 172 21.1 759
The number of total samples, positive results, and prevalence for each age class ap
AMA-1 or MSP-1 antigens.Estimation of seroconversion rates for AMA-1 and MSP-1
The prevalence and the estimated probability of previous
infection as determined by AMA-1 and MSP-1 antigen
response are presented in Figure 5 for the entire study
population (2 to 80 years) and those less than 20 years
of age. The estimated SCR for AMA-1 (top panel) from
the entire study population was 0.016 (SCR – 0.016; 95%
CI = 0.013, 0.018) and 0.014 (SCR – 0.014; 95% CI =
0.012, 0.017) when fit to data from participants 20 years
or younger. For MSP-1 (middle panel), the estimated
SCR from the entire study population was 0.018 (SCR –
0.018; 95% CI = 0.016, 0.021) and 0.019 (SCR – 0.019;
95% CI = 0.015, 0.022) for participants 20 years or youn-
ger. Using AMA-1 or MSP-1 to define seropositive
participants (bottom panel), the estimated SCR from the
entire study population was 0.025 (SCR – 0.025; 95% CI =
0.022, 0.028) and 0.026 (SCR – 0.026; 95% CI = 0.022,
0.302) for participants 20 years or younger. When a non-
zero seroreversion rate (SRR) was used to model the sero-
prevalence data from all participants aged 2 to 80 years of
age, the following conversion and reversion rates were de-
rived: 0.014 (95% CI λ^ 0.011, 0.017) and -0.006 (SRR–
0.006; 95% CI = -0.016, 0.003) for AMA-1 responses,y age class
MSP-1 Combined
No. Pos. % Pos. N No. Pos. % Pos.
5 8.2 61 6 9.8
15 7.9 190 35 18.4
42 21.8 216 58 26.9
36 27.9 154 46 29.9
22 36.7 63 29 46.0
15 37.5 40 15 37.5
23 47.9 50 30 60.0
21 53.8 41 28 68.3
179 23.6 815 247 30.3
pear for participants with positive ELISA results toward AMA-1, MSP-1, or either
Figure 3 Seroprevalence by age class for participants ranging
from 2 to 80 years of age as determined by ELISA using AMA-1
and MSP-1 antigens. The prevalence of samples that had an
response to the AMA-1 or MSP-1 antigens are presented by age
class for those classified as being seropositive with AMA-1 (white),
MSP-1 (charcoal), or either (black dotted) antibodies.
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(SRR – 0.008; 95% CI = -0.005, 0.022) for MSP-1 re-
sponses, and 0.0273 (SCR – 0.0273; 95% CI = 0.022, 0.032)
and 0.007 (SRR – 0.007; 95% CI = -0.003, 0.018) for either
an AMA-1 or MSP-1 response.Figure 4 Comparison of samples with positive AMA-1 or MSP-1
responses. The scatterplot of AMA-1 and MSP-1 responses (average
absorbance at 450 nm) is shown along with the reference lines
denoting positive AMA-1 or MSP-1 responses (dotted lines) using
the threshold absorbance values for previous infection of 0.319 and
0.260 absorbance units, respectively. Samples were positive for
AMA-1 and MSP-1 (region I), MSP-1 positive and AMA-1 negative
(region II), AMA-1 positive and MSP-1 negative (region III), or
negative for both AMA-1 and MSP-1 (region IV). For clarity, samples
with an absorbance value above 1.8 AU are shown as having a
maximum value of 1.8 AU and those with no positive response to
either antigen (region IV) are not shown.Discussion
In an effort to meet the island wide goal of malaria elim-
ination by 2020, the gametocidal drug primaquine (PQ),
was added to the malaria national treatment policy for
Haiti in 2010 [1]. This treatment policy change places
Haiti in a unique position to monitor and quantify the
impact single dose PQ administration has on P. falcip-
arum transmission, which could hold valuable informa-
tion on PQ tolerance and malaria elimination strategies
abroad. Findings suggest that these regions have experi-
ence a relatively low and constant state of P. falciparum
transmission, given the stable increase in seroprevalence
by age observed in this study. In samples that had posi-
tive responses to either AMA-1 or MSP-1, the estimated
SCR of 2.5% (95% CI λ^ 2.2%, 2.8%) from this study is
slightly higher than the <1% prevalence rate estimate by
PSI in 2012 [3]. However, when the seroconversion rates
were determined individually from a positive AMA-1 or
MSP-1 response, the estimated SCR decreased to 1.6%
(95% CI λ^ 1.3%, 1.8%) and 1.8% (95% CI λ^ 1.6%, 2.1%)
for AMA-1 and MSP-1, respectively. The differences in
SCR estimates could be a result in variation in individual
antibody responses, as suggested by Figure 4, where some
seropositive respondents have strong responses to only a
single antigen (regions II and III). Trends were also
observed in the antibody responses after stratification for
age, which could indicate that the duration of AMA-1 and
MSP-1 antibody titers are different, as previously sug-
gested [19]. In Figure 3, in 4 out of 5 age groups below
20 years of age the seroprevalence of MSP-1 was higher
than the seroprevalence of AMA-1, whereas 2 of 3 of the
age groups above 20 show higher seroprevalence of AMA-
1 compared to MSP-1. However, in this sample the
likelihood of participants having a strong AMA-1 response
( > 0.5 AU) and a MSP-1 response below the threshold
(Figure 4, region III) was not significantly different by
age (p > 0.1).
The inclusion of a seroreversion rate in the model also
slightly increased the estimated seroconversion rates. Due
to the cross-sectional nature of this study and the long
duration of antibody detection for AMA-1 and MSP-1, it
was appropriate to set the seroreversion rate to zero. When
seroreversion was included in the model, the seroreversion
rates were -0.006 (95% CI ρ^ -0.016, 0.003) and 0.008 (95%
CI ρ^ -0.005, 0.022) for AMA-1 and MSP-1 respectively.
Since both of the confidence intervals for the seroreversion
rates include zero and the inclusion of a seroreversion rate
in the model had little effect on the estimates of serocon-
version, therefore a priori exclusion of a seroreversion rate
from the final model was justified in this circumstance.
When comparing the estimated seroconversion rates from
study participants under 20 years of age, the continuity in
the age-specific seroprevalence curve could indicate that
over multiple decades, a relatively constant state of low
Figure 5 Seroprevalence estimates for the presence of AMA-1 or MSP-1 antibodies by age for the entire study population. The actual
seroprevalence for AMA-1 and MSP-1 antibodies (circles) appear by age along with the probability of infection in each age class for AMA-1 and
MSP-1 (black lines) and the respective 95% confidence limits (dotted lines), derived from the model estimated seroconversion rate (λ). The top,
middle, and lower panels show the incremental increases in seroprevalence for AMA-1, MSP-1, and either AMA-1 or MSP-1 with age, respectively.
The left panels show the model fits using data from participants 2 years to 20 years of age, while the right panels show the model fits using the
entire data set including participants from 2 to 80 years.
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the absence of sustained malaria control efforts. Entomo-
logical studies investigating the vector competency of A.
albimanus mosquito, may better explain this phenomenon,
of stable low transmission.
Limitations
One of the primary limitations of this study was that
serum samples were collected using a convenience sam-
ple, which limited our ability to infer how this sample
population represents Haiti as a whole. Findings may
have been skewed by potentially enrolling participants
from clinics (n = 203), however, this potential sampling
bias was adequately addressed by excluding all malaria
RDT positive individuals (5/815) from final analysis.
This study also only screened for previous exposure to
P. falciparum, although the likelihood of finding other
species or mixed infections remains low, given recent re-
ports, and the presence of host protective factors [5,20].
As with other ELISA protocols, setting a threshold for theclassification of a sample as seropositive is subject to in-
terpretation. To validate the method used in this study,
thresholds using absorbance values of four and five stand-
ard deviations above the suspected seronegative population
mean were also evaluated and fell within the calculated
confidence intervals for seroprevalence and SCR using
only three standard deviations.
Conclusion
As reported cases of malaria in the Dominican Republic
have reached a 15-year low of 952 cases [1], malaria con-
tinues to be a major public health concern in Haiti. Find-
ings from this study further support the notion of sustained
low low-level transmission in Haiti, while using a highly
sensitive technique that could be used to determine malaria
transmission elsewhere in Haiti. These data suggests that
any efforts to advance malaria control locally have not had
much impact over the last five decades, yet neither have the
past political upheavals or natural disasters from recent
decades resulted in major malaria epidemics.
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gies to other departments in order to establish countrywide
trends. Research examining barriers to access, protective
host characteristics, the extent of heterogeneous malaria
transmission in other departments, and vector proficiency
could also enhance elimination models in Haiti. Elimination
in Haiti appears to be feasible; however, surveillance must
continue to be strengthened in order to respond to areas
with high transmission, while measuring the impact of
future interventions.
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